NEW YORK, August 18, 2020 / PRNewswire / – Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. ("GTT" or the "Company") (NASDAQ: APLT). We recommend that you contact these investors Robert S. Willoughby at the (Email protected) or 888-476-6529, ext. 7980.

The investigation concerns whether Applied and any of its officers and / or directors have committed securities fraud or other illegal business practices.

(Click here for information on how to participate in the class action.)

Up or around May 13, 2019Applied Therapeutics went public ("IPO") and issued 4 million shares of common stock priced at $ 10.00 per share. On 17th August 2020Applied Therapeutics announced that the US Food and Drug Administration ("FDA") has partially clinically discontinued the company's ACTION Kids study evaluating the company's AT-007 product for the treatment of galactosemia. The FDA noted the need for additional technical information to ensure that every participant in the study has access to the drug's benefits.

In the news, Applied Therapeutics' stock fell $ 3.53 per share or 12.07% to close at $ 25.71 per share on 17th August 2020.

The Pomerantz company with offices in new York, Chicago, los Angeles, and Paris is recognized as a leader in corporate, securities and antitrust litigation. Established by the late Abraham L. PomerantzPomerantz Company, known as the dean of class action, pioneered class action lawsuits. Today, more than 80 years later, the Pomerantz company continues its tradition and fights for the rights of victims of securities fraud, fiduciary violations and corporate misconduct. The company has reclaimed numerous millions of dollars in damages on behalf of class members. See

Robert S. Willoughby
Pomerantz LLP
(Email protected)
888-476-6529 ext. 7980

SOURCE Pomerantz LLP

related links

Leave a Reply

Your email address will not be published. Required fields are marked *